In 2017, KCR celebrates its 20-year anniversary of contributing to the clinical R&D industry. The CRO was founded in 1997 by entrepreneur Marek Kiecana. Emerging from Central Europe, KCR today operates in 19 European countries as well as the U.S. and provides pharma and biotech companies with fully customized service solutions for optimized clinical trial execution.
“KCR was registered on May 3rd, 1997, and was one of the first CROs in Central Europe. Our idea was to build a new spot in the clinical research market in the region because of its large population and centralized healthcare system,” said Marek Kiecana, founder of KCR and currently chairman of the KCR Board.
“Being part of such a dynamically developing company like KCR and operating in the challenging contract research market has been a uniquely rewarding experience. When I started this journey 20 years ago, it was hard to imagine that by today KCR would be operating as an international CRO serving customers from all over the world, providing the full spectrum of services.”
KCR rapidly forged a path in Central Europe, Poland, the Czech Republic and the Balkans, and dynamically expanded to the East by setting up branches in Russia, Georgia, Ukraine and Kazakhstan. Being well-established in this part of Europe, KCR has focused on strengthening its footprint in Western Europe over the last few years and on reaching its clients from its new head office in Berlin, Germany.
“We continue our development path as a full service CRO that aligns execution excellence and technology capabilities of a large scale organization with the agility of a 300-plus employees ‘company,” continued Mike Jagielski, CEO of KCR.
KCR would not make a successful story without its clients. “We are proud of having their trust and being part of their drug development programs,” added Mr. Kiecana. In cooperation with our clients we have spent 20 years on executing almost 500 trials, contracting more than 4,000 sites, recruiting near 50,000 patients and monitoring more than 20 therapeutic areas.”
“The world is changing rapidly, so does the clinical trial industry. We are uniquely positioned to engage in the most challenging research projects. Whilst we are satisfied with our achievements to date, we also believe the best for KCR is still yet to come. We would be happy to have our clients celebrating with us this and many more anniversaries,” summarized Jagielski. Please visit KCR for more details.
